Skip to main content
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot. The top 5 remain the same as last year with the only difference being the # 2 slot going to the Hospital for Special Surgery (HSS) in New York City. The other top centers include the Cleveland Clinic, Mayo Clinic and Brigham Hospital.
Predicting Inflammatory Arthritis in At-Risk Persons

The Annals of Internal Medicine has published a predictive score t

Dr. John Cush RheumNow

3 years 2 months ago
Predicting Inflammatory Arthritis in At-Risk Persons The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk IA and who may benefit from risk stratification and preventive measures. https://t.co/I5sLbkvNdT https://t.co/YpOiDYiajW
A novel B-cell depletion trial, using obexelimab (a bifunctional, monoclonal antibody that binds CD19 and Fc gamma receptor IIb), has shown efficacy and safety in patients with active IgG4-related disease.
Hong Kong study shows Very low dose prednisolone (<5 mg/d) doesn't confer excessive CV risk.
2 233 RA pts (105 8

Dr. John Cush RheumNow

3 years 2 months ago
Hong Kong study shows Very low dose prednisolone (<5 mg/d) doesn't confer excessive CV risk. 2 233 RA pts (105 826 Pt-years FUV; mean duration 8.7 yrs) - 7% developed MACE. MACE risk incr 7% per month in those taking ≥5 mg pred. https://t.co/lcehOgaqCQ https://t.co/AhWGnUuYcc
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial l

Dr. John Cush RheumNow

3 years 2 months ago
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given

Dr. John Cush RheumNow

3 years 2 months ago
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/IqCVfOL5rb https://t.co/ocLj7Ejs7A
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with polymyalgia rheumatica (PMR).
Altered Gut Biome in Inflammatory Arthritis
  • MedPage Today
Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear.  In fact, the investigators believe it's probably the other way around.
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA

Dr. John Cush RheumNow

3 years 2 months ago
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells

Dr. John Cush RheumNow

3 years 2 months ago
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells from RA & PsA pts - showing clonal expansion of activated effector CD38hi,CD127−, CD8 T cells, w/ incr type I IFN-assoc transcripts https://t.co/vw2sOGL6jQ https://t.co/uDlt9dH4mQ
Metabolic Burden in the Early Stages of PsA

Dr. Aurelie Najm discusses abstract OP0066 presented at EULAR 2023 in Mila

Dr. John Cush RheumNow

3 years 2 months ago
Metabolic Burden in the Early Stages of PsA Dr. Aurelie Najm discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy. https://t.co/08qOjVJE9A https://t.co/eH6oWsB1dT
The Importance of Knowing Which Entheses are Involved in PsA

Dr. Eric Ruderman discusses abstract POS0027 presented at

Dr. John Cush RheumNow

3 years 2 months ago
The Importance of Knowing Which Entheses are Involved in PsA Dr. Eric Ruderman discusses abstract POS0027 presented at EULAR 2023 in Milan, Italy. https://t.co/nRJfNxwDF0 https://t.co/LUgLQTIUDD
RT @ACR_Journals: New Full Length from A&amp;R:

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexel

ACR_Journals ACR_Journals

3 years 2 months ago
New Full Length from A&R: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns https://t.co/5pzBfiZaNt Created with https://t.co/L5O6lHuNSY https://t.co/HvDy4b1Bg3
The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk inflammatory arthritis (IA) and who may benefit from risk stratification and preventive measures.
Retrospective study of 1877
pts. W/ granulomatosis with polyangiitis (GPA) on RTX found only 23% received TMP-SMX for a

Dr. John Cush RheumNow

3 years 2 months ago
Retrospective study of 1877 pts. W/ granulomatosis with polyangiitis (GPA) on RTX found only 23% received TMP-SMX for a median of 141 days. Prophylaxis was assoc w/ prednisone use (OR 3.96), MTX use (OR 1.48), ICU care (OR 1.95), hospitalization(OR 1.56) https://t.co/JRUC8HUwJU
×